Search Bar & Filters
Found 21 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.
Actively Recruiting
Researchers are evaluating the long-term safety, tolerability, and effectiveness of ML-007C-MA in adults with schizophrenia. This open-label Phase 2 study includes participants who have recently completed a previous related study or new participants enrolling directly. The study focuses on adults aged 18 to 65 diagnosed with schizophrenia who may benefit from ongoing pharmacotherapy and can maintain outpatient care. Participants will receive ML-007C-MA dosed at 2103 mg twice daily for up to 52 weeks. This single-group study does not involve placebo and assesses the medications impact over the treatment period. The study allows for continuous monitoring and adjustment based on the participants response and tolerability. During the study, participants will be involved in regular assessments to monitor safety and tolerability from the initial dose through the entire treatment period. Evaluations include clinical interviews, physical exams, ECGs, and laboratory tests to track any adverse effects or changes in health status. Researchers will also gather information from a reliable informant to support assessments. The total participation duration can be up to one year.
Actively Recruiting
Researchers are evaluating etavopivat, a new oral medicine being developed for blood disorders such as sickle cell disease and thalassaemia. These inherited conditions affect hemoglobin, the protein responsible for carrying oxygen in the body. This long-term study aims to assess the safety and effectiveness of etavopivat treatment over a period of up to 264 weeks, or until the drug is approved in the participants country. Participants will receive one of several oral doses of etavopivat, with dosing adjusted by age those 12 years and older will receive Etavopivat A or C, while children younger than 12 years will receive Etavopivat B. The study involves multiple groups including adults, adolescents, and children with different types of sickle cell disease or thalassaemia. All participants have completed a prior etavopivat treatment study and are continuing treatment in this rollover study. During the study, participants will be regularly monitored for treatment-related side effects and clinical benefits. Researchers will track adverse events, blood crisis rates, hemoglobin levels, hospitalizations, and blood transfusion needs. The study includes long-term safety and efficacy assessments conducted over several years, with monitoring continuing until study completion or drug approval. Participants health and treatment responses will be carefully followed throughout this extended period.
Actively Recruiting
Researchers are evaluating cebranopadol, a drug, to see if multiple doses can reduce opioid withdrawal signs and symptoms in adults with chronic pain who are physically dependent on prescribed opioids. This Phase 2 trial compares two different dosing schedules of cebranopadol with a placebo. The study also examines pain levels, safety, tolerability, and how the drug is processed by the body. Participants will first complete outpatient screening, then be admitted as inpatients for treatment. Their current opioid will be stopped after the morning dose on Day -1 to confirm withdrawal symptoms using specific scales. Those who meet withdrawal criteria will resume opioids briefly before being randomly assigned to one of two cebranopadol dosing regimens or placebo. The study drug is given orally every 12 hours for 48 hours during inpatient stay. Rescue medication is available if needed, and participants resume their prescribed opioids at least 12 hours after the last study dose. During the inpatient treatment, participants undergo assessments for withdrawal, pain, safety, and drug levels. After treatment, they stay monitored until discharge on Day 4. A safety follow-up call is conducted around Day 7. Researchers measure withdrawal severity using the Clinical Opiate Withdrawal Scale over 48 hours as the main outcome, along with other measures of pain, medication use, and safety. The total participation lasts about one week.
Actively Recruiting
Researchers are studying the long-term safety and tolerability of KarXT for treating mania or mania with mixed features in adults with Bipolar-I disorder. This phase 3 open-label extension trial focuses on participants who have either completed prior related studies or are newly diagnosed with specific criteria. The study aims to monitor adverse events and changes in symptoms over an extended period. Participants receive KarXT at specified doses, with some possibly receiving additional therapeutic doses of Lithium, Valproate, or Lamotrigine. The study does not involve placebo and is designed as a single-group intervention. The treatment and monitoring continue for up to 54 weeks, focusing on safety and symptom assessments. During the study, participants undergo regular evaluations including psychiatric assessments and safety monitoring. Researchers track treatment-emergent adverse events, serious adverse events, and changes in suicidal ideation using the Columbia-Suicide Severity Rating Scale. Additional assessments include rating scales for movement disorders and urinary symptoms. The total participation period extends up to about one year, with ongoing safety and tolerability evaluations.
Actively Recruiting
Researchers are evaluating the safety and symptom improvement of ALKS 7290 tablets compared with placebo in adults diagnosed with Attention Deficit Hyperactivity Disorder ADHD. This phase 2, randomized, double-blind study aims to understand how ALKS 7290 affects ADHD symptoms over a four-week period. The study involves adult participants aged 18 to 65 who meet specific diagnostic criteria and have moderate or worse symptom severity. Participants will take ALKS 7290 tablets or placebo capsules daily by mouth for 4 weeks. The trial includes multiple dose levels of ALKS 7290 alongside a placebo group, with treatment effects compared across these groups. The study is designed with a parallel group model and triple blinding to ensure unbiased assessment. Throughout the study, participants will be regularly evaluated for changes in their ADHD symptoms using the Attention Deficit Disorder Investigator Symptom Rating Scale AISRS and the Clinical Global Impression-Severity scale. Safety is monitored by tracking adverse events up to six weeks. Participant health, medication stability, and symptom severity are assessed before and during the trial to measure treatment impact and ensure well-being.
Actively Recruiting
Researchers are evaluating the efficacy and safety of KarXT for treating manic episodes in adults with Bipolar-I Disorder. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults experiencing an acute episode of mania or mania with mixed features. The study aims to compare KarXT to placebo during a 3-week inpatient treatment period to assess symptom improvement. Participants will be randomly assigned to receive either KarXT or a placebo with flexible dosing during the 3-week inpatient phase. Prior to treatment, participants must undergo a screening period and psychotropic medications must be washed out within 14 days before starting. After the treatment phase, there is a safety follow-up period, with the entire study lasting no more than seven weeks. During the study, participants will be hospitalized for close monitoring. Researchers will assess symptoms using the Young Mania Rating Scale and Clinical Global Impressions-Bipolar at baseline and week 3. Safety evaluations will continue through follow-up visits. The main outcome is the change in mania symptoms after 3 weeks of treatment, with additional measures of clinical response and safety observed throughout the study.
Actively Recruiting
Researchers are conducting a Phase 3, randomized, double-blind, placebo-controlled study to evaluate KarXT in adults with Bipolar-I disorder experiencing acute manic or mixed episodes. The study focuses on assessing how well KarXT works compared to a placebo during a three-week inpatient treatment period. Participants must be hospitalized due to their acute symptoms, and the study includes a total duration of up to seven weeks covering screening, treatment, and safety follow-up. Participants are randomly assigned to receive either KarXT or a placebo with flexible dosing during the inpatient phase. The main goal is to observe changes in manic symptoms using the Young Mania Rating Scale over three weeks. The study monitors safety and efficacy through standardized psychiatric assessments and follows participants closely during the inpatient stay. During the trial, participants will undergo regular evaluations including psychiatric ratings and clinical global impressions to track symptom changes and treatment response. The study includes initial screening, a three-week double-blind treatment period while hospitalized, and a safety follow-up period to monitor participants health. The total participation time does not exceed seven weeks.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of SPT-300 GlyphAllo, a prodrug of allopregnanolone, in adults aged 18 to 65 years with major depressive disorder MDD, including those with or without anxious distress. This Phase 2 randomized, double-blind, placebo-controlled study aims to better understand how SPT-300 impacts depressive symptoms compared to placebo. Participants will be randomly assigned to receive either SPT-300 capsules or a matching placebo once daily for 42 days. The study is designed as a parallel-group trial with two arms one receiving the experimental drug SPT-300 and the other receiving placebo. Treatment effects will be closely monitored during this 6-week period. Throughout the study, participants will undergo assessments including the Hamilton Depression Rating Scale-17 HAM-D-17 and the Clinical Global Impression - Severity CGI-S to measure changes in depressive symptoms from baseline to day 42. Safety and tolerability will also be evaluated. The total participation duration extends until study completion in March 2027, with regular visits to monitor progress and well-being.
Actively Recruiting
Researchers are evaluating ACP-211, a medication, to treat adults with major depressive disorder MDD who have not improved with current antidepressant therapy, including those with treatment-resistant depression. This phase 2 trial aims to determine if ACP-211 reduces depression symptoms better than a placebo and to monitor any side effects experienced by participants. Participants are randomly assigned to receive either 600 mg or 300 mg of ACP-211, or a matching placebo, all taken orally twice a week. The study is double-blind, meaning neither participants nor researchers know who receives which treatment, to fairly assess the effects. The main treatment period lasts 28 days with doses given twice weekly. During the study, participants are assessed for changes in depression severity using the Montgomery-sberg Depression Rating Scale MADRS at baseline, day 2, and day 28, among other measures. Additional evaluations include clinical global impression scores and remission rates. Safety and side effects are closely monitored throughout. The total participation time spans from screening to the end of treatment and follow-up, concluding around 28 days after treatment begins.
1-10 of 21
1